Department of Obstetrics and Gynaecology

Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3) (2020) Fasching P, Neven P, Jerusalem G, Beck JT, Chan A, De Laurentiis M, Bianchi GV, et al. Conference contribution Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different (2020) Riecke K, Mueller V, Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mundhenke C, et al. Conference contribution Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial (2020) Jerusalem G, Delea T, Martin Jimenez M, De Laurentiis M, Nusch A, Beck JT, Chan A, et al. Conference contribution Europe-side external quality assessment (EQA) of RNA based testing of ER, PR, HER2 and Ki67 in invasive breast cancer (2020) Erber R, Hartmann A, Fasching P, Stöhr R, Beckmann M, Zentgraf M, Rübner M, et al. Conference contribution "A Stomach Remedy at Birth" [1] a Textbook, "Sola dosis facit venenum" ("Only the dose makes the poison"), Philippus Theophrastus Bombast von Hohenheim, called Paracelsus (1493-1541) (2020) Scharl A, Abou-Dakn M, Kehl S Journal article, Editorial HELLP Syndrome or Acute Fatty Liver of Pregnancy: A Differential Diagnostic Challenge (2020) Rath W, Tsikouras P, Stelzl P Journal article, Review article Influence of Preeclampsia on Induction of Labor at Term: A Cohort Study (2020) Pretscher J, Weiss C, Dammer U, Stumpfe F, Faschingbauer F, Beckmann M, Kehl S Journal article Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial (2020) Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, et al. Journal article, Original article Collective forces of tumor spheroids in three-dimensional biopolymer networks (2020) Mark C, Grundy TJ, Strissel P, Böhringer D, Grummel N, Gerum R, Steinwachs J, et al. Journal article A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial (2020) Karn T, Meissner T, Weber KE, Solbach C, Denkert C, Engels K, Fasching P, et al. Journal article